Chief Accounting Officer
Biocryst Pharmaceuticals Inc (BCRX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Babar Ghias is recorded as CFO and Chief Accounting Officer at Biocryst Pharmaceuticals Inc (BCRX). Biocryst Pharmaceuticals Inc reported in an 8-K filed July 7, 2025 that Babar Ghias was appointed Principal Accounting Officer, effective July 7, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 7, 2025 that Babar Ghias was appointed Chief Financial Officer, effective July 7, 2025. The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $6,748,152 for Babar Ghias in fiscal 2025, including a base salary of $271,515. Babar Ghias has spoken on 5 earnings calls across 1 company, most recently for Biocryst Pharmaceuticals Inc on August 5, 2026.
“Mr. Ghias will also serve as the Company’s Principal Accounting Officer and Head of Corporate Development, effective as of July 7, 2025.”
“On July 7, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced the appointment of Babar Ghias, age 46, as Chief Financial Officer of the Company, effective as of July 7, 2025, and as approved by the Company’s Board of Directors (the “Board”) on June 11, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2025-07-07–present
2025-07-07–present
Start not stated–present
Recorded roles and call appearances connecting this person to public companies.
CFO, Chief Accounting Officer
2025-07-07–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer | $271,515 | $6,748,152 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
